Plan to take part in the second annual event, which last year drew from all sectors of the rapidly growing diagnostics industry, to discuss key issues that will have enormous impact. How will diagnostics change the way compounds are developed and marketed? How does one choose the right biomarker? What is the most reliable route to clinical validation? Will physicians find these new diagnostics tools valuable and reliable enough to use them? How will they be introduced? What is the best business plan to move forward with this biomarker? What commercialization and regulatory issues need to be faced? Hear from key industry and government leaders as we develop a plan for turning this emerging industry into a robust economy.